ITGB2 and acute lymphoblastic leukemia: Blocking antibodies against the corresponding integrins ITGαL and ITGβ1 (Fig. 2b), as well as a small molecule inhibitor of LFA-1 (Fig. 2c), also significantly diminished T-ALL survival.